Loading
A Cambridge company developing Enspyre, a way of enriching tumour DNA so blood tests for leftover cancer need far less sequencing.
Biofidelity Ltd of Cambridge, UK, is the affiliation of the authors of the 2026 Scientific Reports study of Enspyre, a mutation-enrichment ctDNA assay tested on diluted lung cancer plasma.
An experimental blood test from Biofidelity in Cambridge that enriches the tumour's mutated DNA before sequencing, so it needs far less sequencing to find leftover cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/